SCHEMBL2006966

SCHEMBL2006966

CC(=O)OC[C@H]1O[C@@H](OCCNC(=O)OCc2ccccc2)[C@H](NC(=O)OCc2ccccc2)[C@@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.60
▸ KMT2A Q03164 1/20 0.58
▸ POLB P06746 2/20 0.56
▸ MAPT P10636 2/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ TSHR P16473 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ CYP2D6 P10635 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ TGM2 P21980 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MMP12 P39900 1/20 0.40
▸ PAX8 Q06710 1/20 0.40
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006970 1.00 LMNA (0.60) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL21018976 0.95 LMNA (0.65) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL20985072 0.95 LMNA (0.65) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL20985056 0.91 LMNA (0.54) LMNAKMT2APOLBMAPTTSHR
SCHEMBL24239944 0.91 LMNA (0.61) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL31400136 0.91 LMNA (0.61) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL24239907 0.91 LMNA (0.61) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL19935063 0.91 LMNA (0.61) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL22855322 0.90 LMNA (0.63) LMNAKMT2APOLBMAPTCYP3A4
SCHEMBL24699874 0.90 LMNA (0.63) LMNAKMT2APOLBMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960523-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2011-06-14 — — US disclosed
US-20080033155-A1 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2008-02-07 — — US disclosed
US-7288640-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2007-10-30 — — US disclosed
WO-2006012425-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2006-02-02 — — WO disclosed
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor DDOST, AGL, GALE LMNA 4696/4885KMT2A 3470/4885POLB 3579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback